Azitra Inc (AZTR)

May 13, 2026, 8:30 AM EDT - 7 hours ago

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

2026-05-07T06:25:51.000Z - 6 days ago

Azitra granted new U.S. patent protecting ATR-12 program

May 6, 2026, 8:00 AM EDT - 7 days ago

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Apr 28, 2026, 8:02 AM EDT - 15 days ago

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

2026-03-21T00:36:00.000Z - 7 weeks ago

Why Is Azitra Inc Stock (AZTR) Up Today?

2026-03-19T17:45:16.000Z - 7 weeks ago

Azitra Inc trading resumes

Mar 19, 2026, 1:13 PM EDT - 7 weeks ago

Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million

2026-03-19T16:25:35.000Z - 7 weeks ago

Azitra Inc trading halted, news pending

Mar 13, 2026, 5:15 PM EDT - 2 months ago

Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement

Mar 5, 2026, 4:30 PM EST - 2 months ago

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

Feb 27, 2026, 5:30 PM EST - 2 months ago

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

2026-02-24T13:12:53.000Z - 2 months ago

Azitra adds MD Anderson Cancer Center as site for Phase 1/2 skin rash trial

Feb 24, 2026, 8:00 AM EST - 2 months ago

Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash

Feb 19, 2026, 8:00 AM EST - 2 months ago

Azitra, Inc. to Present at BIO Investment & Growth Summit

Feb 6, 2026, 4:15 PM EST - 3 months ago

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Jan 7, 2026, 8:00 AM EST - 4 months ago

Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

2025-12-17T21:16:09.000Z - 5 months ago

Azitra says NYSE American approves compliance plan

Dec 17, 2025, 4:10 PM EST - 5 months ago

Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

2025-12-10T21:16:02.000Z - 5 months ago

Azitra files to sell 38.9M shares of common stock for holders

2025-11-24T14:20:36.000Z - 6 months ago

Azitra prices 4.69M share private placement at 32c per share

Nov 24, 2025, 9:00 AM EST - 6 months ago

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

Nov 12, 2025, 5:15 PM EST - 6 months ago

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

2025-11-07T11:10:47.000Z - 6 months ago

Azitra says report of $44M registered direct offering is false

Nov 7, 2025, 6:00 AM EST - 6 months ago

Azitra, Inc. Addresses False Report Regarding Sale of Securities

2025-10-20T12:10:25.000Z - 7 months ago

Azitra to present preclinical progress for its ATR-01 program

Oct 20, 2025, 8:02 AM EDT - 7 months ago

Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

2025-10-03T20:55:06.000Z - 7 months ago

Azitra receives noncompliance notification from NYSE

Oct 3, 2025, 4:45 PM EDT - 7 months ago

Azitra Receives Notice of Non-Compliance from NYSE American

2025-09-24T12:05:22.000Z - 8 months ago

Azitra price target lowered to $4 from $13.32 at Maxim

Sep 4, 2025, 8:10 AM EDT - 8 months ago

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-28T01:25:00.000Z - 9 months ago

Azitra Stock (AZTR) Rockets on Clinical Trial Update

2025-08-27T12:15:18.000Z - 9 months ago

Azitra doses first patient in Phase 1/2 clinical trial of ATR04-484

Aug 27, 2025, 8:10 AM EDT - 9 months ago

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

Aug 11, 2025, 5:00 PM EDT - 9 months ago

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

2025-08-11T20:21:05.000Z - 9 months ago

Azitra authorizes reverse 1-for-6.66 stock split

Aug 11, 2025, 4:15 PM EDT - 9 months ago

Azitra, Inc. Announces Reverse Stock Split

2025-07-19T02:20:09.000Z - 10 months ago

Azitra files to sell 2.25M shares of common stock for holders

2025-06-17T12:11:19.000Z - 11 months ago

Azitra’s ATR12-351 shows safety in Phase 1b Netherton syndrome trial

Jun 17, 2025, 8:02 AM EDT - 11 months ago

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Jun 10, 2025, 8:33 AM EDT - 1 year ago

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

May 28, 2025, 8:33 AM EDT - 1 year ago

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

May 14, 2025, 4:05 PM EDT - 1 year ago

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

May 13, 2025, 5:06 PM EDT - 1 year ago

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

Apr 25, 2025, 8:33 AM EDT - 1 year ago

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Apr 24, 2025, 4:05 PM EDT - 1 year ago

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Mar 12, 2025, 8:33 AM EDT - 1 year ago

Azitra to Present at Microbiome Times Partnering Forum

Feb 24, 2025, 8:30 AM EST - 1 year ago

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Feb 4, 2025, 2:20 PM EST - 1 year ago

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Feb 3, 2025, 9:05 AM EST - 1 year ago

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Jan 27, 2025, 4:05 PM EST - 1 year ago

Azitra, Inc. to Present at The Microcap Conference

Jan 15, 2025, 8:30 AM EST - 1 year ago

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Jan 14, 2025, 4:05 PM EST - 1 year ago

Azitra Announces Proposed Public Offering of Common Stock

Nov 12, 2024, 5:05 PM EST - 1 year ago

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Oct 29, 2024, 9:00 AM EDT - 1 year ago

Azitra to Present at BIO-Europe 2024

Oct 11, 2024, 9:00 AM EDT - 1 year ago

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Sep 18, 2024, 9:00 AM EDT - 1 year ago

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Aug 20, 2024, 4:15 PM EDT - 1 year ago

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 12, 2024, 6:23 PM EDT - 1 year ago

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Jul 25, 2024, 5:57 PM EDT - 1 year ago

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

Jul 25, 2024, 1:54 PM EDT - 1 year ago

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

HAL

Jul 25, 2024, 1:13 PM EDT - 1 year ago

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

HAL

Jul 23, 2024, 9:20 PM EDT - 1 year ago

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents